drugset / Trial / NCT07602855
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
NaSingle-groupOpen-labelTreatment
Summary
This is an early-phase clinical study investigating a new combination treatment, Ris-Rez given with ivonescimab for adults with advanced solid cancers. The study aims to determine: * What dose(s) of Ris-Rez given with ivonescimab is safe and what are the side effects? * How does the body handle the drug(s)? * What dose of Ris-Rez given with ivonescimab may work best and can improve the treatment of cancer?
Timeline
- Start
- 2026-09-08
- Primary completion
- 2029-07-05
- Completion
- 2030-01-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivonescimab | Monoclonal antibody | — | — |
| Subject | Ris-Rez | Unknown | — | — |